Ovarian Adnexal Mass Assessment Score Test System
ONX is the FDA product code for Ovarian Adnexal Mass Assessment Score Test System, a class II device type, regulated under 21 CFR 866.6050. FDA's definition for this code reads: "An ovarian/adnexal mass assessment test is a devicem that measures one or more proteins in serum. It yields a single result for the likelihood that an adnexal pelvic mass in a woman, for whom surgery is planned, is malignant. The test isn for adjunctive use, in teh context of a negative primary clinical and...". As of , FDA records hold 6 510(k) clearances under this code, the most recent dated , and no recalls.
Classification record
- Product code
- ONX
- Device name
- Ovarian Adnexal Mass Assessment Score Test System
- FDA definition
- An ovarian/adnexal mass assessment test is a devicem that measures one or more proteins in serum. It yields a single result for the likelihood that an adnexal pelvic mass in a woman, for whom surgery is planned, is malignant. The test isn for adjunctive use, in teh context of a negative primary clinical and radiological evaluation, to augmrent the identification of patienets whose gynecologic surgery requires oncology expertise and resources.
- Regulation
- 21 CFR 866.6050
- Device class
- Class II
- Review panel
- Obstetrics/Gynecology
- Submission type
- 510(k)
- Implant
- No
- Life sustaining or supporting
- No
- GMP exempt
- No
- Third party review eligible
- Yes
- Ingested clearances
- 6
- Ingested recalls
- 0
Clearances, product code ONX
By decision yearShow the numbers
| Year | Clearances |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2016 | 4 |
Applicants with the most clearances
Product code ONX| Applicant | Clearances |
|---|---|
| Fujirebio Diagnostics, Inc. | 3 |
| Vermillion | 2 |
| Roche Diagnostics GmbH | 1 |
Companies listing this code with FDA
Companies whose registered establishments list this codeFIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
